Cargando…

Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies

Immune checkpoint blockade therapeutics, notably antibodies targeting the programmed death 1 (PD-1) receptor and its PD-L1 and PD-L2 ligands, are currently revolutionizing the treatment of cancer. For a sizeable fraction of patients with melanoma, lung, kidney and several other solid cancers, monocl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gravelle, Pauline, Burroni, Barbara, Péricart, Sarah, Rossi, Cédric, Bezombes, Christine, Tosolini, Marie, Damotte, Diane, Brousset, Pierre, Fournié, Jean-Jacques, Laurent, Camille
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546533/ https://www.ncbi.nlm.nih.gov/pubmed/28402953 http://dx.doi.org/10.18632/oncotarget.16680

Ejemplares similares

Profiling Immune Escape in Hodgkin’s and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining
por: Péricart, Sarah, et al.
Publicado: (2018)

Several immune escape patterns in non-Hodgkin's lymphomas
por: Laurent, Camille, et al.
Publicado: (2015)

Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma
por: Lamaison, Claire, et al.
Publicado: (2022)

A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
por: Decaup, Emilie, et al.
Publicado: (2019)

Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma
por: Rossi, Cédric, et al.
Publicado: (2020)

Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus
por: Király, Zsófia, et al.
Publicado: (2022)

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1(hi)CD39(+) CD4 T cells
por: Balança, Camille-Charlotte, et al.
Publicado: (2021)

Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma
por: Yokoyama, Shintaro, et al.
Publicado: (2020)

Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation
por: Manson, Guillaume, et al.
Publicado: (2020)

Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma
por: Hollander, Peter, et al.
Publicado: (2018)

Expression of PD-1/PD-L1 in peripheral blood and tumor tissues of patients with classical Hodgkin’s lymphoma
por: Feng, Xia, et al.
Publicado: (2023)

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
por: Damotte, Diane, et al.
Publicado: (2019)

The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China
por: Deng, Mi
Publicado: (2019)

Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma
por: Maekawa, Naoya, et al.
Publicado: (2016)

PD-1, PD-L1 and cAMP immunohistochemical expressions are associated with worse oncological outcome in patients with bladder cancer
por: Russo, Giorgio Ivan, et al.
Publicado: (2022)

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
por: Koh, Young Wha, et al.
Publicado: (2017)

PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition
por: Claaß, Luise Victoria, et al.
Publicado: (2022)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

Immunotherapies in Non-Hodgkin’s Lymphoma
por: Bezombes, Christine, et al.
Publicado: (2021)

High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

18F-Fluorodeoxyglucose positron emission tomography computed tomography detection threshold in follicular lymphoma: A case report
por: Péricart, Sarah, et al.
Publicado: (2017)

Single-cell spatial explorer: easy exploration of spatial and multimodal transcriptomics
por: Pont, Frédéric, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer
por: Fankhauser, Christian D., et al.
Publicado: (2017)

Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency
por: Perrichet, Anaïs, et al.
Publicado: (2020)

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
por: Wang, Yucai, et al.
Publicado: (2018)

S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY
por: Zhang, Huilai, et al.
Publicado: (2023)

Epstein–Barr Virus-Associated T- and NK-Cell Lymphoproliferative Diseases: A Review of Clinical and Pathological Features
por: Syrykh, Charlotte, et al.
Publicado: (2021)

Immunohistochemical Expression of PD-L1 and IDH1 with Detection of MGMT Promoter Methylation in Astrocytoma
por: Hareedy, Amal Ahmed, et al.
Publicado: (2022)

Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine
por: Faria, Carla, et al.
Publicado: (2023)

Programmed Death 1 (PD-1) Expression in Relapsing and Remitting Hodgkin Lymphoma as Prognostic Factor
por: Bouzari, Behnaz, et al.
Publicado: (2023)

Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
por: Watanabe, Takuya, et al.
Publicado: (2018)

Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies
por: Fujisawa, Takuo, et al.
Publicado: (2019)

Immunohistochemical Study of Bladder Cancer Molecular Subtypes and Their Association with PD-L1 Expression
por: Goutas, Dimitrios, et al.
Publicado: (2022)

Immunohistochemical Analysis of PD-1 and FOXP3 in Tumor-Infiltrating Lymphocytes in Human Gliomas
por: Kanagaraj, Priyanka, et al.
Publicado: (2023)

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
por: Tiako Meyo, Manuela, et al.
Publicado: (2020)

Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)

The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma
por: Fang, Xia, et al.
Publicado: (2017)

Management of T-Cell Lymphoma: In Quest of the Holy Grail
por: Péricart, Sarah, et al.
Publicado: (2021)

Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease
por: Tiemann, Markus, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m2drbink9uusi56ehnfkut9k42